Insider · CIK 0001512397
Knighthead Capital Management, LLC
Files at ATIP (ATI Physical Therapy, Inc.). First filing -, latest -.
In brief
Knighthead Capital Management, LLC files SEC Form 4 as director and 10% owner at ATIP (ATI Physical Therapy, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Knighthead Capital Management, LLC has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 30, 2024 | ATIP ATI Physical Therapy, Inc. | AGrant or award Series B Preferred Stockindirect: See Footnote | +12,000 | $0.00 | $0 | 64,383 | Feb 8, 2024 |
| Jan 30, 2024 | ATIP ATI Physical Therapy, Inc. | AGrant or award Convertible PIK Notes (Delayed Draw)derivativeindirect: See Footnote | +960,000 | - | - | 960,000 | Feb 8, 2024 |
Questions about Knighthead Capital Management, LLC
Answered from the filings on this page, as of the latest one.
Is Knighthead Capital Management, LLC buying or selling?
Knighthead Capital Management, LLC has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Knighthead Capital Management, LLC's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Knighthead Capital Management, LLC has 0.
Where does Knighthead Capital Management, LLC file Form 4?
Knighthead Capital Management, LLC has filed Form 4 at ATIP (ATI Physical Therapy, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.